Blanco José R, Jarrín Inmaculada, Vallejo Manuel, Berenguer Juan, Solera Carmen, Rubio Rafael, Pulido Federico, Asensi Victor, del Amo Julia, Moreno Santiago
Hospital San Pedro-CIBIR, Logroño, Spain.
AIDS Res Hum Retroviruses. 2012 Sep;28(9):1000-6. doi: 10.1089/AID.2011.0377.
The age of 50 has been considered as a cut-off to discriminate older subjects within HIV-infected people according to the Centers for Disease Control and Prevention (CDC). However, the International AIDS Society (IAS) mentions 60 years of age and the Department of Health and Human Services (DHHS) makes no consideration. We aimed to establish an age cut-off that could differentiate response to highly active antiretroviral therapy (HAART) and, therefore, help to define advanced age in HIV-infected patients. CoRIS is an open, prospective, multicenter cohort of HIV adults naive to HAART at entry (January 2004 to October 2009). Survival, immunological response (IR) (CD4 increase of more than 100 cell/ml), and virological response (VR) (HIV RNA less than 50 copies/ml) were compared among 5-year age intervals at start of HAART using Cox proportional hazards models, stratified by hospital and adjusted for potential confounders. Among 5514 patients, 2726 began HAART. During follow-up, 2164 (79.4%) patients experienced an IR, 1686 (61.8%) a VR, and 54 (1.9%) died. Compared with patients aged <25 years at start of HAART, those aged 50-54, 55-59, 60-64, 65-59, and 70 or older were 32% (aHR: 0.68, 95% CI: 0.52-0.87), 29% (aHR: 0.71, 95% CI: 0.53-0.96), 34% (aHR: 0.66, 95% CI: 0.46-0.95), 39% (aHR: 0.61, 95% CI: 0.37-1.00), and 43% (aHR: 0.57, 95% CI: 0.31-1.04) less likely to experience an IR. The VR was similar across all age groups. Finally, patients aged 50-59 showed a 3-fold increase (aHR: 3.58; 95% CI: 1.07-11.99) in their risk of death compared to those aged <30 years. In HIV infection, patients aged ≥50 years have a poorer immunological response to HAART and a poorer survival. This age could be used to define medically advanced age in HIV-infected people.
根据美国疾病控制与预防中心(CDC)的标准,50岁被视为区分HIV感染者中老年人群的界限。然而,国际艾滋病协会(IAS)提出的界限是60岁,而美国卫生与公众服务部(DHHS)则未作考量。我们旨在确定一个年龄界限,以区分对高效抗逆转录病毒疗法(HAART)的反应,从而有助于界定HIV感染患者的高龄状态。CoRIS是一个开放、前瞻性、多中心队列,纳入了初始未接受过HAART的HIV成年患者(2004年1月至2009年10月)。使用Cox比例风险模型,在HAART开始时按5年年龄间隔比较生存情况、免疫反应(IR)(CD4细胞计数增加超过100个/毫升)和病毒学反应(VR)(HIV RNA低于50拷贝/毫升),按医院分层并对潜在混杂因素进行校正。在5514例患者中,2726例开始接受HAART。随访期间,2164例(79.4%)患者出现IR,1686例(61.8%)出现VR,54例(1.9%)死亡。与HAART开始时年龄<25岁的患者相比,年龄在50 - 54岁、55 - 59岁、60 - 64岁、65 - 69岁和70岁及以上的患者出现IR的可能性分别降低32%(校正后风险比[aHR]:0.68,95%置信区间[CI]:0.52 - 0.87)、29%(aHR:0.71,95% CI:0.53 - 0.96)、34%(aHR:0.66,95% CI:0.46 - 0.95)、39%(aHR:0.61,95% CI:0.37 - 1.00)和43%(aHR:0.57,95% CI:0.31 - 1.04)。各年龄组的VR相似。最后,与年龄<30岁的患者相比,年龄在50 - 59岁的患者死亡风险增加了3倍(aHR:3.58;95% CI:1.07 - 11.99)。在HIV感染中,年龄≥50岁的患者对HAART的免疫反应较差,生存情况也较差。这个年龄可用于界定HIV感染人群中的医学高龄状态。